CDMO may accelerate the mass production of COVID-19 vaccine candidates.

AS A CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION FOR BIOLOGICS, VIRAL VACCINES AND GENE THERAPY (CDMO), FUJIFILM DIOsynTH BIOTECHNOLOGY TODAY ANNOUNCED THAT IT WILL SUPPORT THE PRODUCTION OF THE COVID-19 CANDIDATE VACCINE, WITH THE AIM OF STARTING TO DELIVER MILLIONS OF SAFE AND EFFECTIVE DOSES OF THE COVID-19 VACCINE TO THE AMERICAN PUBLIC.
FUOSFILM Diosynth Biotech announced on July 23 that it had reached an agreement with Novavax to produce the API for NVX-CoV2373 at its plant in North Carolina.
technology transfer from North Carolina to Texas will begin in late 2020, and mass production of candidate vaccines will begin in early 2021. "Our scientists and engineers are proud to support the production of the COVID-19 vaccine," said Dr. Gerry Farrell, Chief Operating Officer, FUJIFILM Diosynth Biotechnology,
.
contract processing outsourcing (CMO) is mainly commissioned by pharmaceutical companies to provide product production required process development, formulation development, clinical trial drug use, chemical or biosynthetic API production, intermediate manufacturing, preparation production and other services.
CDMO is a more market-adapted form derived from CMO.
.